Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Peter Impey

- PMLiVE

Nestlé and Seres announce new partnership for C.diff microbiome therapeutic

The companies will jointly commercialise Seres’ investigational oral microbiome therapeutic in the US and Canada

- PMLiVE

Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies

By George Forsyth

- PMLiVE

J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant

Vaccine produces durable immune responses lasting up to eight months

- PMLiVE

COVID-19 booster dose programme planned for September launch in Britain

The programme will be conducted in two stages for a range of priority groups

- PMLiVE

The importance of the human touch

by  Kirstie Turner

- PMLiVE

The love/hate relationship between creativity and data in healthcare

by Alisa Shakarian

- PMLiVE

Elliott Management puts pressure on GSK after years of ‘disappointing performance’

Hedge fund has published a 17-page letter outlining recommendations following GSK's investor day last week

- PMLiVE

COUCH Health taps Mark Duman for chief strategy officer role

Duman has over 30 years of experience working in the healthcare sector

- PMLiVE

Ashfield Engage appoints Serap Becker as head of patient solutions in DACH region

Prior to joining Ashfield Engage, Becker served as director of direct to patient services at Marken

Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma

Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also...

Impetus Digital

Moving Away from Hospital-Centered Care: Barriers & Opportunities

David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips...

Impetus Digital

- PMLiVE

Cambridge University scientists identify 160 new drugs with COVID-19 repurposing potential

Scientists highlighted the potential of two drugs, one for rheumatoid arthritis and one for malaria

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links